Anna Minchom

2.5k total citations
110 papers, 1.1k citations indexed

About

Anna Minchom is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Anna Minchom has authored 110 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Oncology, 63 papers in Pulmonary and Respiratory Medicine and 21 papers in Molecular Biology. Recurrent topics in Anna Minchom's work include Lung Cancer Treatments and Mutations (43 papers), Cancer Immunotherapy and Biomarkers (19 papers) and Cancer Genomics and Diagnostics (18 papers). Anna Minchom is often cited by papers focused on Lung Cancer Treatments and Mutations (43 papers), Cancer Immunotherapy and Biomarkers (19 papers) and Cancer Genomics and Diagnostics (18 papers). Anna Minchom collaborates with scholars based in United Kingdom, United States and Spain. Anna Minchom's co-authors include Juanita Lopez, Caterina Aversa, Mary O’Brien, Kate Young, Jaishree Bhosle, James Larkin, Joshua Bauml, Sanjay Popat, Sai‐Hong Ignatius Ou and Santiago Viteri and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Anna Minchom

101 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anna Minchom United Kingdom	19	697	605	343	154	118	110	1.1k
Joyce Cheng United States	13	596 0.9×	370 0.6×	244 0.7×	229 1.5×	84 0.7×	31	943
Tindara Franchina Italy	19	749 1.1×	633 1.0×	487 1.4×	311 2.0×	98 0.8×	60	1.3k
Gonzalo Recondo United States	15	637 0.9×	576 1.0×	386 1.1×	313 2.0×	103 0.9×	54	1.1k
Florian Guisier France	19	718 1.0×	901 1.5×	247 0.7×	216 1.4×	84 0.7×	102	1.2k
Paolo Bironzo Italy	18	505 0.7×	637 1.1×	334 1.0×	191 1.2×	111 0.9×	100	1.2k
Jingyu Yu United States	15	871 1.2×	439 0.7×	286 0.8×	143 0.9×	224 1.9×	27	1.3k
Judit Moldvay Hungary	20	735 1.1×	599 1.0×	447 1.3×	247 1.6×	92 0.8×	79	1.3k
Thomas Goddemeier Germany	9	966 1.4×	930 1.5×	352 1.0×	179 1.2×	101 0.9×	18	1.3k
Sofía Braga Portugal	17	931 1.3×	430 0.7×	431 1.3×	357 2.3×	150 1.3×	52	1.5k
Geoffrey Kim United States	18	621 0.9×	354 0.6×	205 0.6×	142 0.9×	156 1.3×	29	1.0k

Countries citing papers authored by Anna Minchom

Since Specialization

Citations

This map shows the geographic impact of Anna Minchom's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Minchom with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Minchom more than expected).

Fields of papers citing papers by Anna Minchom

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Minchom. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Minchom. The network helps show where Anna Minchom may publish in the future.

Co-authorship network of co-authors of Anna Minchom

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Minchom. A scholar is included among the top collaborators of Anna Minchom based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Minchom. Anna Minchom is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zachariou, Athanasios, Sudhir Venkatesan, Xiaolin Hu, et al.. (2025). 85P: Phase I results from the phase I/II POTENT trial of tepotinib and pembrolizumab in non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology. 20(3). S62–S63.

Minchom, Anna, O. Lindén, Raffit Hassan, et al.. (2025). First-in-human study of a thorium-227-labeled mesothelin-targeting antibody-chelator conjugate (MSLN-TTC), in patients with malignant mesothelioma and other solid tumors. ESMO Open. 10(12). 105905–105905.

Liu, Jia, Anna Minchom, Alastair Greystoke, et al.. (2025). Dendrimer-Nanoparticle (DEP) Delivery of Topoisomerase I Inhibitor, SN38 (DEP-SN38): Safety, Tolerability, and Preliminary Efficacy Study in Patients With Advanced Solid Tumors. Journal of Clinical Oncology. 43(26). 2918–2929. 1 indexed citations

Leighl, Natasha B., Hiroaki Akamatsu, Ying Cheng, et al.. (2024). Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial.. Journal of Clinical Oncology. 42(17_suppl). LBA8505–LBA8505. 12 indexed citations

Liu, Jia, Anna Minchom, Alastair Greystoke, et al.. (2024). Dendrimer-enhanced (DEP) SN38 (DEP irinotecan) in patients (pts) with advanced solid tumors: A phase 1/2 trial.. Journal of Clinical Oncology. 42(16_suppl). 3014–3014. 1 indexed citations

Rehman, Faisal, Nadia Yousaf, Carol Tan, et al.. (2024). 81 Evaluation of neoadjuvant chemo-immunotherapy for operable non-small cell lung cancer: clinical outcomes and impact on service delivery. Lung Cancer. 190. 107642–107642.

Lai‐Kwon, Julia, Anna Minchom, Olalekan Lee Aiyegbusi, et al.. (2022). Using Patient-Reported Outcomes in Dose-Finding Oncology Trials: Surveys of Key Stakeholders and the National Cancer Research Institute Consumer Forum. The Oncologist. 27(9). 768–777. 6 indexed citations

Coker, Elizabeth A., Adam Stewart, Buğra Özer, et al.. (2022). Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence–Enabled Studies of Acute Phosphoproteomic Changes. Molecular Cancer Therapeutics. 21(6). 1020–1029. 8 indexed citations

Joshi, Kroopa, Nadia Yousaf, Sanjay Popat, et al.. (2021). Safety monitoring of two and four-weekly adjuvant durvalumab for patients with stage III NSCLC: implications for the COVID-19 pandemic and beyond. Lung Cancer. 156. 147–150. 5 indexed citations

10.

Virtakoivu, Reetta, Jenna H. Rannikko, Miro Viitala, et al.. (2021). Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial. Clinical Cancer Research. 27(15). 4205–4220. 41 indexed citations

11.

Pal, Abhijit, Andrea Biondo, Alex Pui‐Wai Lee, et al.. (2021). A Wolf in Sheep's Clothing: Systemic Immune Activation Post Immunotherapy. SHILAP Revista de lepidopterología. 4(4). 189–195. 5 indexed citations

12.

Banerjee, Susana, João Paulo da Silveira Nogueira Lima, Matthew Krebs, et al.. (2021). 725MO Phase I study of the combination of the dual RAF/MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Results of efficacy in low grade serous ovarian cancer. Annals of Oncology. 32. S728–S728. 11 indexed citations

13.

Terbuch, Angelika, Mariana Scaranti, Andra Curcean, et al.. (2020). Radiological Patterns of Drug-induced Interstitial Lung Disease (DILD) in Early-phase Oncology Clinical Trials. Clinical Cancer Research. 26(18). 4805–4813. 13 indexed citations

14.

Bono, Petri, Panu Jaakkola, Shishir Shetty, et al.. (2020). 1024MO A phase I/II MATINS trial: Part 1 pharmacokinetic, safety and efficacy results of Clever-1 blockade in advanced cancer. Annals of Oncology. 31. S706–S707. 1 indexed citations

15.

Lai‐Kwon, Julia, et al.. (2020). 585P Trends in patient-reported outcome (PRO) use in early phase oncology trials. Annals of Oncology. 31. S495–S495. 3 indexed citations

16.

Stewart, Adam, Elizabeth A. Coker, Sebastian Pölsterl, et al.. (2019). Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS -Mutant Cancers. Molecular Cancer Therapeutics. 18(8). 1396–1404. 14 indexed citations

17.

Minchom, Anna, Jacqueline Filshie, Jaishree Bhosle, et al.. (2017). P3.05-006 Anxiolytic Effect of Acupuncture in a Phase II Study of Acupuncture and Morphine for Dyspnea in Lung Cancer and Mesothelioma. Journal of Thoracic Oncology. 12(1). S1415–S1416. 1 indexed citations

18.

Minchom, Anna, Jacqueline Filshie, Jaishree Bhosle, et al.. (2016). A randomised study comparing the effectiveness of acupuncture or morphine versus the combination for the relief of dyspnoea in patients with advanced non-small cell lung cancer and mesothelioma. European Journal of Cancer. 61. 102–110. 37 indexed citations

19.

Young, Kate, Anna Minchom, David Cunningham, & Ian Chau. (2012). Neoadjuvant chemotherapy for gastric cancer. 1(3). 202–204. 11 indexed citations

20.

Minchom, Anna, et al.. (2010). An Unusual Case of Pancreatic Cancer with Leptomeningeal Infiltration. Journal of Gastrointestinal Cancer. 41(2). 107–109. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact